Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

Phase 3KSI-501afliberceptPositive

AI Analysis

Summary

Kodiak Sciences announced the first patient enrollment in its Phase 3 ALTO trial evaluating KSI-501 versus aflibercept in diabetic macular edema patients, with the trial designed to demonstrate superiority of the investigational therapy.

Clinical Trial Data

Phase

Outcome Details

First patients enrolled in Phase 3 ALTO trial

Importance:5/10

Sentiment:

0.60

Phase_3_TrialClinical_DevelopmentDiabetic_Macular_EdemaRetinaTrial_Initiation

Related Companies

$KOD

Read the original article

Published by PR Newswire Pharma on August 10, 2026 8:43 PM

Read Original